Mereo BioPharma Group Management
Management criteria checks 4/4
Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.9% of the company’s shares, worth $10.83M. The average tenure of the management team and the board of directors is 6.7 years and 3.6 years respectively.
Key information
Denise Scots-Knight
Chief executive officer
US$2.2m
Total compensation
CEO salary percentage | 25.5% |
CEO tenure | 9.3yrs |
CEO ownership | 1.9% |
Management average tenure | 6.7yrs |
Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$45m |
Jun 30 2024 | n/a | n/a | -US$37m |
Mar 31 2024 | n/a | n/a | -US$26m |
Dec 31 2023 | US$2m | US$565k | -US$29m |
Sep 30 2023 | n/a | n/a | -US$31m |
Jun 30 2023 | n/a | n/a | -US$32m |
Mar 31 2023 | n/a | n/a | -US$42m |
Dec 31 2022 | US$2m | US$507k | -US$42m |
Sep 30 2022 | n/a | n/a | -US$31m |
Jun 30 2022 | n/a | n/a | -US$23m |
Mar 31 2022 | n/a | n/a | -US$4m |
Dec 31 2021 | US$2m | US$539k | US$17m |
Sep 30 2021 | n/a | n/a | -US$10m |
Jun 30 2021 | n/a | n/a | -US$37m |
Mar 31 2021 | n/a | n/a | -US$131m |
Dec 31 2020 | US$1m | US$545k | -US$224m |
Sep 30 2020 | n/a | n/a | -US$198m |
Jun 30 2020 | n/a | n/a | -US$177m |
Mar 31 2020 | n/a | n/a | -US$111m |
Dec 31 2019 | US$2m | US$518k | -US$46m |
Sep 30 2019 | n/a | n/a | -US$41m |
Jun 30 2019 | n/a | n/a | -US$40m |
Mar 31 2019 | n/a | n/a | -US$41m |
Dec 31 2018 | US$957k | US$484k | -US$41m |
Sep 30 2018 | n/a | n/a | -US$42m |
Jun 30 2018 | n/a | n/a | -US$44m |
Mar 31 2018 | n/a | n/a | -US$50m |
Dec 31 2017 | US$907k | US$493k | -US$52m |
Compensation vs Market: Denise's total compensation ($USD2.22M) is about average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Denise's compensation has been consistent with company performance over the past year.
CEO
Denise Scots-Knight (65 yo)
9.3yrs
Tenure
US$2,219,323
Compensation
Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.3yrs | US$2.22m | 1.9% $ 10.8m | |
Co-Founder | 9.5yrs | US$1.09m | 0.58% $ 3.3m | |
Chief Financial Officer | 3.8yrs | US$1.00m | 0.27% $ 1.5m | |
Co-Founder & Chief Business Officer | 9.8yrs | no data | no data | |
Chief Scientific Officer | 4.3yrs | no data | 0.060% $ 341.6k | |
Senior VP & Therapeutic Head | no data | no data | no data | |
Chief of Patient Access & Commercial Planning | 6.7yrs | no data | 0.033% $ 185.8k | |
Senior Vice President of Clinical Development | 3.9yrs | no data | no data | |
Senior VP and Head of Pharmaceutical Development & CMC | no data | no data | no data |
6.7yrs
Average Tenure
62yo
Average Age
Experienced Management: MREO's management team is seasoned and experienced (6.7 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.7yrs | US$2.22m | 1.9% $ 10.8m | |
Independent Non-Executive Chairman of The Board | 5.6yrs | US$156.80k | 0.016% $ 92.2k | |
Independent Non-Executive Director | 5.6yrs | US$113.76k | 0% $ 0 | |
Independent Non-Executive Director | 9.3yrs | US$121.31k | 0.17% $ 941.9k | |
Independent Director | 2yrs | US$94.49k | 0.049% $ 277.5k | |
Independent Director | 2yrs | US$100.96k | 0.049% $ 277.5k | |
Independent Non Executive Director | 4.1yrs | US$105.08k | 0.0081% $ 46.2k | |
Independent Director | 2yrs | US$97.75k | 0.049% $ 277.5k | |
Independent Director | 3.2yrs | US$102.18k | 0.10% $ 569.1k | |
Independent Director | 2yrs | no data | no data |
3.6yrs
Average Tenure
59yo
Average Age
Experienced Board: MREO's board of directors are considered experienced (3.6 years average tenure).